Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Lambert, Nicolas; Dauby, Solène; DIVE, Dominique; SADZOT, Bernard; MAQUET, Pierre

doi:10.3201/eid2801.204809

Request a copy

Article (Scientific journals)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Lambert, Nicolas; Dauby, Solène; DIVE, Dominique et al.

2022 • In Emerging Infectious Diseases, 28 (1)

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/265782

DOI
10.3201/eid2801.204809

PubMed
34856110

Files (4)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Manuscript Atezolizumab for PML Clean.docx

Author preprint (31.13 kB)

Request a copy

Annexes

Figure.pdf

Publisher postprint (515.49 kB)

Figure

Request a copy

Appendix 1 .pdf

Publisher postprint (2.81 MB)

Appendix 1

Request a copy

Appendix 2.pdf

Publisher postprint (603.55 kB)

Appendix 2

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

atzolizumab; progressive multifocal leukoencephalopathy; Jc virus

Abstract :

[en] Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in immune reconstitution inflammatory syndrome and life-threatening immune-related adverse events. These conditions were treated with corticosteroids, leading to treatment resistance.

Disciplines :

Neurology
Immunology & infectious disease
Neurology
Immunology & infectious disease

Author, co-author :

Lambert, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

Dauby, Solène ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

DIVE, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Unité de revalidation neurologique (Esneux)

SADZOT, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

MAQUET, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

Language :

English

Title :

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Publication date :

January 2022

Journal title :

Emerging Infectious Diseases

ISSN :

1080-6040

eISSN :

1080-6059

Publisher :

U.S. National Center for Infectious Diseases, United States - Georgia

Volume :

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 06 December 2021

Statistics

Number of views

91 (8 by ULiège)

Number of downloads

12 (8 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021; 17:37-51. https://doi.org/10.1038/s41582-020-00427-y
Beck ES, Cortese I. Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. Curr Opin Virol. 2020; 40:19-27. https://doi.org/10.1016/j.coviro.2020.02.005
Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013; 80:1430-8. https://doi.org/10.1212/WNL.0b013e31828c2fa1
Antoniol C, Jilek S, Schluep M, Mercier N, Canales M, Le Goff G, et al. Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management? Neurology. 2012; 79:2258-64. https://doi.org/10.1212/WNL.0b013e3182768983
Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, et al. Selective inhibition of lowaffinity memory CD8+ T cells by corticosteroids. J Exp Med. 2019; 216:2701-13. https://doi.org/10.1084/jem.20190738
Tan CS, Bord E, Broge TA Jr, Glotzbecker B, Mills H, Gheuens S, et al. Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr. 2012; 60:244-8. https://doi.org/10.1097/QAI.0b013e31825a313c
Audemard-Verger A, Gasnault J, Faisant M, Besse MC, Martin-Silva N, Berra M, et al. Sustained response and rationale of programmed cell death-1-targeting for progressive multifocal leukoencephalopathy. Open Forum Infect Dis. 2019; 6:ofz374. https://doi.org/10.1093/ofid/ofz374
Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 2010; 3:81-91. https://doi.org/10.1038/mi.2009.112
Kon E, Benhar I. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resist Updat. 2019; 45:13-29. https://doi.org/10.1016/j.drup.2019.07.004
Medrano C, Vergez F, Mengelle C, Faguer S, Kamar N, Del Bello A. Effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy. Emerg Infect Dis. 2019; 25:2145-7. https://doi.org/10.3201/eid2511.190705